3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
64
Colonic Neoplasms
19
Rectal Neoplasms
12
Esophageal Neoplasms
9
Neoplasms
8
Neoplasm Metastasis
8
Cholangiocarcinoma
7
Squamous Cell Carcinoma of Head and Neck
6
Pancreatic Neoplasms
6
Breast Neoplasms
6
Colorectal Cancer Metastatic
5
Carcinoma, Non-Small-Cell Lung
5
Triple Negative Breast Neoplasms
4
Head and Neck Neoplasms
4
Ovarian Neoplasms
3
Inflammatory Breast Neoplasms
3
Carcinoma, Squamous Cell
3
Adenocarcinoma Of Esophagus
3
Adenocarcinoma
3
Urinary Bladder Neoplasms
2
Stomach Neoplasms
2
Recurrence
2
Prostatic Neoplasms
2
Lung Neoplasms
2
Glioma
2
Gastrointestinal Neoplasms
2
Carcinoma
2
Biliary Tract Neoplasms
2
Unspecified Adult Solid Tumor, Protocol Specific
1
Solid Tumors
1
Interventions
trifluridine tipiracil drug combination
1
Trastuzumab
1
Panitumumab
1
Oxaliplatin
1
Nivolumab
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Dihydropyrimidine Dehydrogenase Deficiency
×
Panitumumab
×
Clear all
NCT06245356
2025-12-10
TRIFLUOX-DP
UNICANCER
Phase 2
Recruiting
73 enrolled